U.S. Markets close in 2 hrs 9 mins

EnteroMedics Inc. (ETRM)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.38-0.10 (-2.23%)
As of 1:51PM EDT. Market open.
People also watch
IDXGPULMBIOCXGTIGLBS
Full screen
Previous Close4.48
Open4.46
Bid4.35 x 4400
Ask4.38 x 200
Day's Range4.32 - 4.46
52 Week Range0.04 - 30.41
Volume62,547
Avg. Volume469,546
Market Cap30.25M
Beta2.67
PE Ratio (TTM)-0.38
EPS (TTM)-11.42
Earnings DateMay 4, 2017 - May 8, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Trade prices are not sourced from all markets
  • EnteroMedics Announces Receipt of European Patent Certificate
    PR Newswire4 days ago

    EnteroMedics Announces Receipt of European Patent Certificate

    ST. PAUL, Minn., July 20, 2017 /PRNewswire/ -- EnteroMedics Inc. (ETRM), a developer of minimally invasive medical devices to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the receipt of a European Patent Certificate.  The Company was granted Patent number 2254659 titled "Treatment of excess weight by neural downregulation in combination with compositions."  The patent pertains to EU protection of a system for combination therapy and corresponds with the Company's US intellectual property.

  • EnteroMedics Announces Affordable vBloc® Therapy Program for Weight Loss Patients
    PR Newswire26 days ago

    EnteroMedics Announces Affordable vBloc® Therapy Program for Weight Loss Patients

    ST. PAUL, Minn., June 28, 2017 /PRNewswire/ -- EnteroMedics Inc. (ETRM), the developer of medical devices to treat obesity, metabolic diseases, and other obesity-related comorbidities, announced today the launch of the vBloc Now program. The program provides qualified patients access to vBloc® Therapy at a reduced cost in partnership with select bariatric and weight loss centers across the United States. "We've repeatedly stated that our goal remains broad coverage and reimbursement for vBloc Therapy," said Dan Gladney, EnteroMedics President, Chief Executive Officer, and Chairman of the Board.

  • EnteroMedics Added to Russell Microcap® Index
    PR Newswire28 days ago

    EnteroMedics Added to Russell Microcap® Index

    ST. PAUL, Minn., June 26, 2017 /PRNewswire/ -- EnteroMedics Inc. (ETRM), the developer of medical devices to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the Company will join the Russell Microcap® Index effective after the U.S. market opens today. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. "EnteroMedics is very pleased to be added to such a widely referenced index," said Dan Gladney, EnteroMedics President, Chief Executive Officer and Chairman of the Board.